Mylan, now part of Viatris (VTRS), had its challenge of two of Novo Nordisk’s (NVO) GLP-1 patents denied, according to Bloomberg.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTRS:
- Early notable gainers among liquid option names on October 2nd
- Viatris agrees to divest Women’s Healthcare unit, API unit in India
- Viatris receives offer for divestiture of substantially all of OTC business
- Viatris announces agreements on remaining planned divestitures
- Viatris (NASDAQ:VTRS) Rises on Key Business Divestments